IBD Evidence

Airteagal

Cad is cúis le IBD? Géineolaíocht, timpeallacht, minicíocht

Updated 4 min read 60 citations

Snáithe endasóscópach le haghaidh polypectomy gastrointestinal uachtarach agus colónach
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Ní mhíníonn ná géineolaíocht ná timpeallacht galar boilg athlastach as a stuaim féin. Insíonn an ghéineolaíocht duit cé atá so-ghabhálach; insíonn an eipidéimeolaíocht duit nach féidir le so-ghabhálacht amháin a bheith ina scéal iomlán, toisc go bhfuil léarscáil dhomhanda an ghalair bogtha róthapa le go mínódh géinte é.

Cad a thaispeánann an ghéineolaíocht i ndáiríre

Tá staidéir chomhcheangail ar fud an ghéanóim tar éis líon suntasach lócas a bhaineann le so-ghabhálacht IBD a aithint. D'aithin meiteanailís sonraí comhcheangail 38 lócas so-ghabhálachta agus léirigh sé riosca géiniteach atá roinnte ar fud daonraí agus, go suntasach, roinnte go páirteach le galair eile atá idirghabhtha ag an gcóras imdhíonachta [25]. Chuir staidéar comhcheangail ar fud an ghéanóim ar leith i leith gníomhachtú imdhíonachta go leor géinte integrin go sonrach [24] — toradh atá suimiúil ó thaobh meicníochta de, ós rud é go n-oibríonn cógais a bhlocálann integrin (an aicme bhitheolaíoch frith-integrin a chumhdaítear ar ár leathanach cóireála) trí chosán trádála na leucaicítí a bhfuil na géinte seo suite ann a bhriseadh go díreach.

Tá an ceacht praiticiúil ón ngéineolaíocht níos cúinge ná mar a mheasann daoine. Ní galar aon-ghéine, oidhreachtúil Mendelian é IBD — is polaigéiniúil é, agus go leor lócas ag cur méid beag riosca leis gach ceann. Má tá gaol den chéad chéim agat le IBD, méadaíonn sé sin an riosca os cionn an ghnáthdhaonra, ach ní fhorbraíonn an galar go deo i bhformhór mór na ndaoine a iompraíonn athróga géiniteacha a bhaineann le IBD. Socraíonn géineolaíocht tairseach so-ghabhálachta; cinneann rud éigin eile an dtrasnaítear an tairseach sin.

Cén fáth nach féidir leis an ngéineolaíocht a bheith mar an scéal iomlán

Ní athraíonn ailtireacht ghéiniteach daonra thar chúpla scór bliain. Tá minicíocht dhomhanda IBD tar éis athrú. Rianaíonn anailís ó 2025 in Nature minicíocht IBD trasna a bhfuil ar a dtugtar céimeanna eipidéimeolaíocha — minicíocht íseal, céim luasghéaraithe agus an mhinicíocht ag ardú go géar, ansin céim chothromaíochta réimsiúlachta comhdhéanaimh ina n-ardaíonn an mhinicíocht go plátó ach a leanann líon na ndaoine a mhaireann leis an ngalar ag dul suas toisc gur galar ainsealach é [35]. Tá réigiúin atá ag tionsclú go nua inniu ag gluaiseacht tríd an gcéim luasghéaraithe ar ghluais Iarthar na hEorpa agus Meiriceá Thuaidh tríthi thar an bhfichiú haois.

Rinneadh an patrún seo a dhoiciméadú níos luaithe in athbhreithniú córasach ar staidéir bunaithe ar dhaonraí faoi mhinicíocht agus réimsiúlacht dhomhanda [23], agus cuireann athbhreithniú breise a dhíríonn go sonrach ar eipidéimeolaíocht trasna na n-aoiseanna in aois na dteiripí ardleibhéil an pictiúr domhanda reatha i gcomhthéacs [33]. Fuair athbhreithniú córasach a dhírigh ar IBD a thosaíonn i leanaí an treocht luasghéaraithe chéanna go sonrach i leanaí agus i ndéagóirí [15], agus rinneadh treochtaí ospidéalaithe thar an tréimhse chéanna a shaintréithiú in athbhreithniú córasach breise le hanailísí ama [7].

Is é patrún geografach agus ama a leanann tionsclú seachas seachmall géiniteach an argóint is láidre atá ar fáil go bhfuil rud éigin faoin gcaoi a maireann daonra — ní hamháin an chaoi a saolaítear é — ag déanamh cuid shuntasach den obair chúiseach.

Na hiarrthóirí timpeallachta

Scrúdaigh athbhreithniú scátha ar mheiteanailísí fachtóirí riosca timpeallachta le haghaidh IBD go díreach, ag tabhairt le chéile na fianaise trasna go leor staidéar nochta aonair i sintéis amháin [20]. Is é achoimre ionraic na litríochta seo go bhfuil fianaise thacúil ag roinnt iarrthóirí de neart éagsúil, agus nár léiríodh go bhfuil aon cheann acu leordhóthanach as a stuaim féin — comhsheasmhach le galar a d'fhéadfadh a éileamh go réasúnta go dtarlódh teagmhas duine atá so-ghabhálach ó thaobh géineolaíochta le teaglaim ar leith nochta.

An t-aon sócmhainn amháin: conas a oireann na píosaí le chéile

Catagóir fachtóraCad atá bunaitheCad nach bhfuil
So-ghabhálacht ghéiniteachAithníodh na scórtha lócas a chuireann leis; braitheann riosca i dteaghlaigh agus roinneann sé meicníochtaí le galair imdhíonachta eileNíl aon ghéin amháin riachtanach ná leordhóthanach; ní fhorbraíonn formhór na ndaoine atá so-ghabhálach ó thaobh géineolaíochta de IBD go deo
Patrún geografach/amaArdaíonn minicíocht go géar de réir mar a thionsclaítear réigiúin, ansin sroicheann sí plátó agus réimsiúlacht ag leanúint ag ardúTaispeánann an patrún go bhfuil tábhacht leis an timpeallacht; ní shainaithníonn sé as a stuaim féin cé acu nochtadh is tábhachtaí
Nochtaí timpeallachta aonairTá athbhreithniú scátha tar éis an litríocht nochta a shintéisiú trasna go leor fachtóirí iarrthóraNíl aon fhachtóir timpeallachta amháin bunaithe mar riachtanach nó leordhóthanach as a stuaim féin
An idirghníomhaíochtRéasúnta agus comhsheasmhach le patrún foriomlán na sonraí: so-ghabhálacht móide nochtadhNí intomhaiste go díreach le dearaí staidéir reatha ag an leibhéal aonair

Cén fáth a bhfuil sé seo tábhachtach go praiticiúil

Ní athraíonn aon cheann de seo bainistíocht. Ní shainaithníonn sé bia le seachaint, athrú stíl mhaireachtála atá ráthaithe chun lasadh a chosc, ná tástáil a thuarann riosca aonair le beachtas úsáideach. An rud a mhíníonn sé ná dhá rud a insítear go minic go neamhréireach d'othair: nach "gcruthaíonn" aiste bia ná strus IBD ar aon bhealach simplí (tá géineolaíocht agus athruithe timpeallachta ar leibhéal an daonra ag déanamh i bhfad níos mó den obair chúiseach ná roghanna laethúla), agus nach mí-ádh géiniteach amháin é ach oiread (cuireann an mhinicíocht atá ag ardú i réigiúin atá ag tionsclú go nua deireadh leis sin as a stuaim féin). Bíonn claonadh ag an dá athfhrámáil sin an ciontacht a thuairiscíonn othair maidir le "cad a rinne mé chun é seo a chruthú" a laghdú — ceist nach dtacaíonn an bunús fianaise léi a chur i leith aon iompar aonair i ndáiríre.

Ceisteanna coitianta

An bhfuil IBD oidhreachtúil? An bhfaighidh mo leanaí é?
Tá riosca méadaithe i ngaolta den chéad chéim de dhuine a bhfuil IBD orthu, ach ní fhorbraíonn formhór mór na ngaolta go deo é. Is patrún géine so-ghabhálachta é, ní galar oidhreachtúil Mendelian.
Ar chruthaigh rud éigin a d'ith mé nó a rinne mé mo IBD?
Níor bunaíodh aon fhachtóir aiste bia nó stíl mhaireachtála amháin mar chúis leordhóthanach. Díríonn an fhianaise ar theaglaim de so-ghabhálacht ghéiniteach agus nochtaí timpeallachta ar leibhéal an daonra ag titim amach thar blianta, ní ar spreagthóir aonair inaitheanta.
Cén fáth a bhfuil IBD ag éirí níos coitianta i dtíortha ina raibh sé neamhchoitianta roimhe seo?
Leanann sé seo tionsclú go dlúth go leor gurb í ceann de na hargóintí is láidre é ar son comhpháirte timpeallachta — ní athraíonn géinte go tapa go leor lena mhíniú, agus doiciméadaíodh an patrún anois trasna go leor réigiún agus tréimhsí ama.
Má mhíníonn géineolaíocht so-ghabhálacht amháin, cad é an truicear iarbhír?
Níl sé bunaithe go beacht. Cuireadh nochtaí comhshaoil is iarrthóirí le chéile i bhfianaise athbhreithnithe scátha, ach níor léiríodh go bhfuil aon fhachtóir amháin riachtanach nó leordhóthanach — fanann sé seo ina réimse oscailte taighde seachas ceist réitithe.
Trí chapsúl ceamara a úsáidtear chun íomhá a dhéanamh den ineachán, den phutóg chaol agus den phutóg mhór
Glacann capsúil slogtha grianghraif de shínte den phutóg chaol nach féidir le heindeascóp traidisiúnta a bhaint amach. Dr.HH.Krause · CC BY-SA 3.0 · Wikimedia Commons
An cruthúnas atá taobh thiar den leathanach seo Bar stacked ag taispeáint comhoibriú na 30 foilseacháin atá luaite ar an leathanach seo de réir cineál staidéir. 2563meta-analysis (25)randomised trial (6)review (3)other (1)
35 foils, 2015–2026. Is é sin meascán le trialacha agus sintéis ann, atá mar an suíomh óna bhfuil éileamh faoi chúis réasúnta. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Mediterranean diet in treatment of inflammatory bowel disease: A systematic review and meta-analysis Singh A, Rana U, Chandnani S, et al. · Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026 · Meta-analysis DOIPubMed 41803562
  3. Study Design Complexity and Participant Completion in Dietary Trials for Inflammatory Bowel Disease: A Systematic Review and Metaresearch Study Gregersen L, Moos C, Hikmat Z, et al. · Advances in nutrition (Bethesda, Md.) · 2026 · Systematic review DOIPubMed 41825595Full text
  4. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  5. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  6. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  7. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  8. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  9. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. Pre-Illness Index-Based Dietary Patterns and Inflammatory Bowel Disease Risk: A Systematic Review and Meta-Analysis Meng F, Zhang T, Meng X, et al. · Nutrition reviews · 2025 · Meta-analysis DOIPubMed 40700526
  12. Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review Gleave A, Shah A, Tahir U, et al. · The American journal of gastroenterology · 2025 · Systematic review DOIPubMed 39056556
  13. Efficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders-A Systematic Review of Randomized Controlled Trials Kuźmin L, Kubiak K, Lange E · Nutrients · 2025 · Systematic review DOIPubMed 40573159Full text
  14. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  15. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes Zheng T, Roda G, Zabana Y, et al. · Journal of Crohn's & colitis · 2024 · Meta-analysis DOIPubMed 37768647
  16. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  17. Efficacy of different dietary therapy strategies in active pediatric Crohn's disease: a systematic review and network meta-analysis Ma J, Chong J, Qiu Z, et al. · PeerJ · 2024 · Meta-analysis DOIPubMed 39686992Full text
  18. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  19. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  20. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  21. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  22. High-Fiber Diet and Crohn's Disease: Systematic Review and Meta-Analysis Serrano Fernandez V, Seldas Palomino M, Laredo-Aguilera JA, et al. · Nutrients · 2023 · Meta-analysis DOIPubMed 37513532Full text
  23. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis Herrador-López M, Martín-Masot R, Navas-López VM · Nutrients · 2023 · Meta-analysis DOIPubMed 37836478Full text
  24. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  25. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  26. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  27. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  28. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  29. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  30. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease Sinopoulou V, Gordon M, Akobeng AK, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34844288Full text
  31. Systematic Review of the Effects of Oat Intake on Gastrointestinal Health Valido E, Stoyanov J, Bertolo A, et al. · The Journal of nutrition · 2021 · Systematic review DOIPubMed 34486656
  32. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  33. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  34. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  35. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses Piovani D, Danese S, Peyrin-Biroulet L, et al. · Gastroenterology · 2019 · Meta-analysis DOIPubMed 31014995
  36. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  37. ESPEN guideline: Clinical nutrition in inflammatory bowel disease Forbes A, Escher J, Hébuterne X, et al. · Clinical nutrition (Edinburgh, Scotland) · 2017 · Systematic review DOIPubMed 28131521
  38. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  39. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  40. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  41. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419
  42. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text
  43. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis Li F, Liu X, Wang W, et al. · European journal of gastroenterology & hepatology · 2015 · Meta-analysis DOIPubMed 25831134
  44. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis Zhou XL, Xu W, Tang XX, et al. · BMC gastroenterology · 2014 · Meta-analysis DOIPubMed 25002150Full text
  45. Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial Wellens J, Vanderstappen J, Hoekx S, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Randomised controlled trial DOIPubMed 40816342
  46. A Randomised Controlled Trial Comparing the Effects of Personalised Diet and Physical Activity Intervention Versus Usual Care on Cardiometabolic Risk Factors in Adults with Inactive Inflammatory Bowel Disease Yap JM, Wall CL, Meredith-Jones K, et al. · Nutrients · 2026 · Randomised controlled trial DOIPubMed 41829955Full text
  47. Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study Minato I, Mena P, Ricciardiello L, et al. · Molecular nutrition & food research · 2025 · Randomised controlled trial DOIPubMed 40255128Full text
  48. Effects of bromelain supplementation on disease activity and quality of life in patients with ulcerative colitis: a randomized, triple-blind, placebo-controlled study Delgarm P, Mokhtare M, Ebrahimi Daryani N, et al. · Scientific reports · 2025 · Randomised controlled trial DOIPubMed 41315628Full text
  49. Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial Aharoni-Frutkoff Y, Plotkin L, Pollak D, et al. · Gastroenterology · 2025 · Randomised controlled trial DOIPubMed 40553742
  50. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial Pasta A, Formisano E, Calabrese F, et al. · European journal of clinical investigation · 2025 · Randomised controlled trial DOIPubMed 39853756
  51. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  52. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial Yanai H, Levine A, Hirsch A, et al. · The lancet. Gastroenterology & hepatology · 2022 · Randomised controlled trial DOIPubMed 34739863
  53. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  54. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition Svolos V, Hansen R, Nichols B, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 30550821
  55. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial Levine A, Wine E, Assa A, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 31170412
  56. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  57. Chronic, Noninfectious Diarrhea: A Review Singh P, Lee A, Sheth NM, et al. · JAMA · 2026 · Review DOIPubMed 41770539
  58. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  59. Mild Crohn's Disease: Definition and Management Claytor J, Kumar P, Ananthakrishnan AN, et al. · Current gastroenterology reports · 2023 · Review DOIPubMed 36753033
  60. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original